Literature DB >> 26040571

Therapeutic targets of triple-negative breast cancer: a review.

Vinayak S Jamdade1, Nikunj Sethi2,3, Nitin A Mundhe1, Parveen Kumar1, Mangala Lahkar1,4, Neeraj Sinha2,3.   

Abstract

Breast cancer (BC) is the second most common cause of cancer deaths. Triple-negative breast cancer (TNBC) does not show immunohistochemical expression of oestrogen receptors, progesterone receptors or HER2. At present, no suitable treatment option is available for patients with TNBC. This dearth of effective conventional therapies for the treatment of advanced stage breast cancer has provoked the development of novel strategies for the management of patients with TNBC. This review presents recent information associated with different therapeutic options for the treatment of TNBC focusing on promising targets such as the Notch signalling, Wnt/β-catenin and Hedgehog pathways, in addition to EGFR, PARP1, mTOR, TGF-β and angiogenesis inhibitors.
© 2015 The British Pharmacological Society.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26040571      PMCID： PMC4556464          DOI： 10.1111/bph.13211

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  71 in total

1.  The mutation without children(rgl) causes ecdysteroid deficiency in third-instar larvae of Drosophila melanogaster.

Authors:  J Wismar; N Habtemichael; J T Warren; J D Dai; L I Gilbert; E Gateff
Journal:  Dev Biol       Date:  2000-10-01       Impact factor: 3.582

2.  Confirmation of the mapping of the Camurati-Englemann locus to 19q13. 2 and refinement to a 3.2-cM region.

Authors:  S P Vaughn; S Broussard; C R Hall; A Scott; S H Blanton; J M Milunsky; J T Hecht
Journal:  Genomics       Date:  2000-05-15       Impact factor: 5.736

Review 3.  The Wnt/β-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer.

Authors:  Taj D King; Mark J Suto; Yonghe Li
Journal:  J Cell Biochem       Date:  2012-01       Impact factor: 4.429

Review 4.  A review of triple-negative breast cancer.

Authors:  Roohi Ismail-Khan; Marilyn M Bui
Journal:  Cancer Control       Date:  2010-07       Impact factor: 3.302

5.  Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination.

Authors:  Niklas Schultz; Elena Lopez; Nasrollah Saleh-Gohari; Thomas Helleday
Journal:  Nucleic Acids Res       Date:  2003-09-01       Impact factor: 16.971

Review 6.  The primary cilia, a 'Rab-id' transit system for hedgehog signaling.

Authors:  Anthony E Oro
Journal:  Curr Opin Cell Biol       Date:  2007-12-03       Impact factor: 8.382

7.  Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation.

Authors:  S M Wahl; D A Hunt; H L Wong; S Dougherty; N McCartney-Francis; L M Wahl; L Ellingsworth; J A Schmidt; G Hall; A B Roberts
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

8.  Patched acts catalytically to suppress the activity of Smoothened.

Authors:  J Taipale; M K Cooper; T Maiti; P A Beachy
Journal:  Nature       Date:  2002-08-22       Impact factor: 49.962

9.  The Concise Guide to PHARMACOLOGY 2013/14: enzymes.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 10.  Salinomycin as a drug for targeting human cancer stem cells.

Authors:  Cord Naujokat; Roman Steinhart
Journal:  J Biomed Biotechnol       Date:  2012-11-21
View more
  64 in total

Review 1.  Metastatic breast cancer: The Odyssey of personalization.

Authors:  A Sonnenblick; N Pondé; M Piccart
Journal:  Mol Oncol       Date:  2016-07-11       Impact factor: 6.603

Review 2.  Recent advances in liposome formulations for breast cancer therapeutics.

Authors:  Biyao Yang; Bo-Ping Song; Shaina Shankar; Anna Guller; Wei Deng
Journal:  Cell Mol Life Sci       Date:  2021-05-11       Impact factor: 9.261

3.  Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).

Authors:  Chandraiah Godugu; Ravi Doddapaneni; Mandip Singh
Journal:  Colloids Surf B Biointerfaces       Date:  2017-01-23       Impact factor: 5.268

4.  Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer.

Authors:  Chandraiah Godugu; Ravi Doddapaneni; Stephen H Safe; Mandip Singh
Journal:  Eur J Pharm Biopharm       Date:  2016-08-30       Impact factor: 5.571

5.  MELK as a potential target to control cell proliferation in triple-negative breast cancer MDA-MB-231 cells.

Authors:  Gang Li; Mei Yang; Li Zuo; Mei-Xing Wang
Journal:  Oncol Lett       Date:  2018-04-20       Impact factor: 2.967

6.  Optical and Magnetic Resonance Imaging Using Fluorous Colloidal Nanoparticles.

Authors:  Jaqueline D Wallat; Anna E Czapar; Charlie Wang; Amy M Wen; Kristen S Wek; Xin Yu; Nicole F Steinmetz; Jonathan K Pokorski
Journal:  Biomacromolecules       Date:  2016-12-19       Impact factor: 6.988

7.  Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance.

Authors:  Richard Marcotte; Azin Sayad; Kevin R Brown; Felix Sanchez-Garcia; Jüri Reimand; Maliha Haider; Carl Virtanen; James E Bradner; Gary D Bader; Gordon B Mills; Dana Pe'er; Jason Moffat; Benjamin G Neel
Journal:  Cell       Date:  2016-01-14       Impact factor: 41.582

8.  Dual targeting of Notch and Wnt/β-catenin pathways: Potential approach in triple-negative breast cancer treatment.

Authors:  Fatma Nasser; Nermine Moussa; Maged W Helmy; Medhat Haroun
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-10-14       Impact factor: 3.000

9.  Short SULF1/SULF2 splice variants predominate in mammary tumours with a potential to facilitate receptor tyrosine kinase-mediated cell signalling.

Authors:  Roop Ms Gill; Vedika Mehra; Emma Milford; Gurtej K Dhoot
Journal:  Histochem Cell Biol       Date:  2016-06-13       Impact factor: 4.304

10.  TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties.

Authors:  Kelly Kyker-Snowman; Robert M Hughes; Christopher L Yankaskas; Karen Cravero; Swathi Karthikeyan; Berry Button; Ian Waters; David Marc Rosen; Lauren Dennison; Natasha Hunter; Josh Donaldson; Eric S Christenson; Konstantinos Konstantopoulos; Paula J Hurley; Sarah Croessmann; Ben Ho Park
Journal:  Breast Cancer Res Treat       Date:  2019-12-10       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.